Cerulean Reports Fourth Quarter 2015 Corporate Highlights and Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Leerink Partners Cuts Price Target on Cerulean Pharma (CERU) to $8; Reiterates Outperform
March 11, 2016 7:20 AM ESTLeerink Partners maintained an Outperform rating on Cerulean Pharma (NASDAQ: CERU), and cut the price target to $8.00 (from $10.00), following the company's 4Q.
Analyst Michael Schmidt commented, "CERU reported 4Q results and provided an update on its clinical nanoparticle drug-conjugate (NDC) pipeline consisting of... More
